485 related articles for article (PubMed ID: 22918778)
121. Impact of 68Ga-DOTATOC PET/CT in comparison to 111In-Octreotide SPECT/CT in management of neuro-endocrine tumors: A case report.
Tolomeo A; Lopopolo G; Dimiccoli V; Perioli L; Modoni S; Scilimati A
Medicine (Baltimore); 2020 Feb; 99(7):e19162. PubMed ID: 32049844
[TBL] [Abstract][Full Text] [Related]
122. Clinical utility of
Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
[TBL] [Abstract][Full Text] [Related]
123. Dosimetry of
Xu L; Meng Q; Yao X; Yang R; Zhang P; Li R; Wang F
Appl Radiat Isot; 2022 Jan; 179():109975. PubMed ID: 34741954
[TBL] [Abstract][Full Text] [Related]
124. Preoperative assessment of lymph nodal metastases with [
Mapelli P; Bezzi C; Muffatti F; Ghezzo S; Canevari C; Magnani P; Schiavo Lena M; Battistella A; Scifo P; Andreasi V; Partelli S; Chiti A; Falconi M; Picchio M
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2774-2783. PubMed ID: 38696129
[TBL] [Abstract][Full Text] [Related]
125. (68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT.
Kroiss A; Shulkin BL; Uprimny C; Frech A; Gasser RW; Url C; Gautsch K; Madleitner R; Nilica B; Sprinzl GM; Gastl G; Fraedrich G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):33-41. PubMed ID: 25134670
[TBL] [Abstract][Full Text] [Related]
126. Radio-Guided Surgery with a New-Generation β-Probe for Radiolabeled Somatostatin Analog, in Patients with Small Intestinal Neuroendocrine Tumors.
Bertani E; Mattana F; Collamati F; Ferrari ME; Bagnardi V; Frassoni S; Pisa E; Mirabelli R; Morganti S; Fazio N; Fumagalli Romario U; Ceci F
Ann Surg Oncol; 2024 Jul; 31(7):4189-4196. PubMed ID: 38652200
[TBL] [Abstract][Full Text] [Related]
127. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
[TBL] [Abstract][Full Text] [Related]
128. Detection of cranial meningiomas: comparison of ⁶⁸Ga-DOTATOC PET/CT and contrast-enhanced MRI.
Afshar-Oromieh A; Giesel FL; Linhart HG; Haberkorn U; Haufe S; Combs SE; Podlesek D; Eisenhut M; Kratochwil C
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1409-15. PubMed ID: 22669255
[TBL] [Abstract][Full Text] [Related]
129. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Schuhmacher J; Haberkorn U; Karkavitsas N; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):460-6. PubMed ID: 16437218
[TBL] [Abstract][Full Text] [Related]
130. Impact of Tumor Burden on Quantitative [
Werner RA; Hänscheid H; Leal JP; Javadi MS; Higuchi T; Lodge MA; Buck AK; Pomper MG; Lapa C; Rowe SP
Mol Imaging Biol; 2019 Aug; 21(4):790-798. PubMed ID: 30406512
[TBL] [Abstract][Full Text] [Related]
131. Value of
Imperiale A; Boursier C; Sahakian N; Ouvrard E; Chevalier E; Sebag F; Addeo P; Taïeb D
J Nucl Med; 2022 Mar; 63(3):384-388. PubMed ID: 34272321
[TBL] [Abstract][Full Text] [Related]
132. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
133. 177 Lu-DOTATATE (Lutathera) Therapy in 68 Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor.
Ventura D; Roll W; Kasper HU; Rahbar K; Stegger L
Clin Nucl Med; 2023 Dec; 48(12):e585-e587. PubMed ID: 37883194
[TBL] [Abstract][Full Text] [Related]
134. Differential Detection of Hepatic Metastases on 68 Ga-DOTATATE PET/CT and 177 Lu-DOTATATE SPECT/CT.
Zahed H; Beauregard JM; Abikhzer G; Rush C; Probst S
Clin Nucl Med; 2023 Jan; 48(1):e12-e15. PubMed ID: 36240803
[TBL] [Abstract][Full Text] [Related]
135. Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review.
Nisa L; Savelli G; Giubbini R
Ann Nucl Med; 2011 Feb; 25(2):75-85. PubMed ID: 21107762
[TBL] [Abstract][Full Text] [Related]
136. Bilateral Orbital Soft-Tissue Metastases from Renal Neuroendocrine Tumor: Successful Theranostic Application of
Parghane RV; Basu S
J Nucl Med Technol; 2019 Jun; 47(2):171-172. PubMed ID: 30139884
[TBL] [Abstract][Full Text] [Related]
137. Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by
Jahn U; Ilan E; Velikyan I; Fröss-Baron K; Lubberink M; Sundin A
EJNMMI Res; 2021 Nov; 11(1):118. PubMed ID: 34822040
[TBL] [Abstract][Full Text] [Related]
138. Equivalent Dose Rate 1 Meter from Neuroendocrine Tumor Patients Exiting the Nuclear Medicine Department After Undergoing Imaging.
Zhang-Yin J; Dirand AS; Sasanelli M; Corrégé G; Peudon A; Kiffel T; Nataf V; Clerc J; Montravers F; Talbot JN
J Nucl Med; 2017 Aug; 58(8):1230-1235. PubMed ID: 28209907
[No Abstract] [Full Text] [Related]
139. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group.
Chinol M; Bodei L; Cremonesi M; Paganelli G
Semin Nucl Med; 2002 Apr; 32(2):141-7. PubMed ID: 11965609
[TBL] [Abstract][Full Text] [Related]
140. Treatment with
Estorch M
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):69-71. PubMed ID: 28257748
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]